Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

7.290 -0.250 (-3.32%)
Streaming Delayed Price Updated: 2:22 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
4 Analysts Assess Bicycle Therapeutics: What You Need To Know
 
Via Benzinga
Bicycle (BCYC) Q2 Revenue Falls 69%
Via The Motley Fool
Topics Intellectual Property
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
 
Via Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Deep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics
 
Via Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views
 
Via Benzinga
A Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 Analysts
 
Via Benzinga
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
From Bicycle Therapeutics plc
Via Business Wire
Analyst Expectations For Bicycle Therapeutics's Future
 
Via Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification. 
Via Benzinga
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.